Cardinal Health announced the commencement of weekly production of actinium-225 (Ac-225) through its Center for Theranostics Advancement in Indianapolis, Indiana. This initiative is a collaboration with TerraPower Isotopes and marks a significant milestone in increasing access to theranostics.
The routine production establishes Cardinal Health as the first to provide cGMP Ac-225 globally at scale. This will enhance the availability of Ac-225 for the manufacturing of investigational therapeutic drug products and future commercial production of novel therapies.
Ac-225 is an alpha-emitting radionuclide crucial for targeted alpha therapies (TATs) currently being evaluated in clinical studies for various cancers, including prostate, neuroendocrine, breast, colon, melanoma, and lymphoma. This investment underscores Cardinal Health's commitment to supporting innovative precision medicines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.